Next Article in Journal
Comparison of Gene Expression Profiles of Uropathogenic Escherichia Coli CFT073 after Prolonged Exposure to Subinhibitory Concentrations of Different Biocides
Next Article in Special Issue
Combating Antimicrobial Resistance in Singapore: A Qualitative Study Exploring the Policy Context, Challenges, Facilitators, and Proposed Strategies
Previous Article in Journal
Stability of Biological Activity of Frozen β-lactams over Time as Assessed by Time-Lapsed Broth Microdilutions
Previous Article in Special Issue
Actinomycete-Derived Polyketides as a Source of Antibiotics and Lead Structures for the Development of New Antimicrobial Drugs
Open AccessCommentary

Challenges for Economic Evaluation of Health Care Strategies to Contain Antimicrobial Resistance

Centre for Health Economics and Medicines Evaluation (CHEME), Bangor University, Normal Site, Bangor, Gwynedd LL57 2PZ, UK
*
Author to whom correspondence should be addressed.
Antibiotics 2019, 8(4), 166; https://doi.org/10.3390/antibiotics8040166
Received: 20 August 2019 / Revised: 15 September 2019 / Accepted: 24 September 2019 / Published: 27 September 2019
(This article belongs to the Special Issue Feature Paper in Antibiotics for 2019)
The threat of antimicrobial resistance has global health and economic consequences. Medical strategies to reduce unnecessary antibiotic prescribing, to conserve the effectiveness of current antimicrobials in the long term, inevitably result in short-term costs to health care providers. Economic evaluations of health care interventions therefore need to consider the short-term costs of interventions, to gain future benefits. This represents a challenge for health economists, not only in terms of the most appropriate methods for evaluation, but also in attributing the potential budget impact over time and considering health impacts on future populations. This commentary discusses the challenge of accurately capturing the cost-effectiveness of health care interventions aimed at tackling antimicrobial resistance. We reflect on methods to capture and incorporate the costs and health outcomes associated with antimicrobial resistance, the appropriateness of the quality-adjusted-life year (QALY), individual time preferences, and perspectives in economic evaluation. View Full-Text
Keywords: antimicrobial resistance; economic evaluation; cost-utility analysis; cost-effectiveness analysis; antibiotics antimicrobial resistance; economic evaluation; cost-utility analysis; cost-effectiveness analysis; antibiotics
MDPI and ACS Style

Holmes, E.A.F.; Hughes, D.A. Challenges for Economic Evaluation of Health Care Strategies to Contain Antimicrobial Resistance. Antibiotics 2019, 8, 166.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop